Glaucoma medication and aqueous humor dynamics

Current Opinion in Ophthalmology

Volumn 16, Issue 2, 2005, Pages 94-100

  Crowston, Jonathan G ^a   Weinreb, Robert N ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Aqueous humor dynamics; Glaucoma; Outflow facility; Topical medication

Indexed keywords

1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; ADRENALIN; AFP 168; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIMATOPROST; BRIMONIDINE; BRINZOLAMIDE; CARBONATE DEHYDRATASE INHIBITOR; DORZOLAMIDE; LATANOPROST; PILOCARPINE; PROSTAGLANDIN F2 ALPHA DERIVATIVE; TAFLUPROST; TIMOLOL; TIMOLOL MALEATE; UNCLASSIFIED DRUG; ANTIHYPERTENSIVE AGENT;

AQUEOUS HUMOR FLOW; CLINICAL TRIAL; CYTOSKELETON; EXTRACELLULAR MATRIX; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; MEASUREMENT; NONHUMAN; PARAMETER; PRIORITY JOURNAL; REVIEW; ANIMAL; AQUEOUS HUMOR; METABOLISM; SECRETION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; AQUEOUS HUMOR; GLAUCOMA; HUMANS;

EID: 17044374115     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.icu.0000156136.20570.eb     Document Type: Review

References (61)

1. The Advanced Glaucoma Intervention Study (AGIS). 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol 2000; 130:429-440.
2. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120:701-713. [discussion 829-730]
3. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002; 120:1268-1279.
4. Asrani S, Zeimer R, Wilensky J, et al. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma 2000; 9:134-142.
5. Drance SM. The significance of the diurnal tension variations in normal and glaucomatous eyes. Arch Ophthalmol 1960; 64:494-501.
6. Zeimer RC, Wilensky JT, Gieser DK, et al. Association between intraocular pressure peaks and progression of visual field loss. Ophthalmology 1991; 98:64-69.
7. Liu JH, Zhang X, Kripke DF, et al. Twenty-four-hour intraocular pressure pattern associated with early glaucomatous changes. Invest Ophthalmol Vis Sci 2003; 44:1586-1590.
8. Wilensky JT. The role of diurnal pressure measurements in the management of open angle glaucoma. Curr Opin Ophthalmol 2004; 15:90-92.
9. Becker B, Neufeld AH. Pressure dependence of uveoscleral outflow. J Glaucoma 2002; 11:545.
10. Weinreb RN, Toris CB, Gabelt BT, et al. Effects of prostaglandins on the aqueous humor outflow pathways. Surv Ophthalmol 2002; 47(Suppl 1):S53-S64.
11. Brubaker RF. Goldmann's equation and clinical measures of aqueous dynamics. Exp Eye Res 2004; 78:633-637. Outlines the limitations of the techniques used for measuring aqueous humor dynamics. Makes a case for revising the Goldmann equation and reinterpreting its parameters.
12. Bill A, Phillips CI. Uveoscleral drainage of aqueous humour in human eyes. Exp Eye Res 1971; 12:275-281.
13. Toris CB, Yablonski ME, Wang YL, et al. Aqueous humor dynamics in the aging human eye. Am J Ophthalmol 1999; 127:407-412.
14. Weinreb RN. See comments in Editors Selection. International Glaucoma Reviews 2003, 5(2).
15. Townsend DJ, Brubaker RF. Immediate effect of epinephrine on aqueous formation in the normal human eye as measured by fluorophotometry. Invest Ophthalmol Vis Sci 1980; 19:256-266.
16. Christiansen GA, Nau CB, McLaren JW, et al. Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma. Ophthalmology 2004; 111:1658-1662. Prospective, randomized, crossover study in ocular hypertensive and glaucoma patients. Bimatoprost increased tonographic outflow facility by 47% and pressure-insensitive flow by 95%. Bimatoprost also reduced peak IOP in the water-drinking test.
17. Gabelt BT, Kaufman PL. The effect of prostaglandin F2 alpha on trabecular outflow facility in cynomolgus monkeys. Exp Eye Res 1990; 51:87-91.
18. Camras CB. Some thoughts on the pressure dependence of uveoscleral flow [author reply 93-94]. J Glaucoma 2003; 12:92-93.
19. Bill A. The aqueous humor drainage mechanism in the cynomolgous monkey (Macaca Irus) with evidence of unconventional routes. Invest Ophthalmol 1965; 4:911-919.
20. Gabelt BT, Kaufman PL. Prostaglandin F2 alpha increases uveoscleral outflow in the cynomolgus monkey. Exp Eye Res 1989; 49:389-402.
21. Gabelt BT, Gottanka J, Lutjen-Drecoll E, et al. Aqueous humor dynamics and trabecular meshwork and anterior ciliary muscle morphologic changes with age in rhesus monkeys. Invest Ophthalmol Vis Sci 2003; 44:2118-2125. Physiological and structural changes in the monkey uveoscleral outflow pathways are similar to age-related changes in the human eye.
22. Aihara M, Lindsey JD, Weinreb RN. Aqueous humor dynamics in mice. Invest Ophthalmol Vis Sci 2003; 44:5168-5173.
23. Aihara M, Lindsey JD, Weinreb RN. Episcleral venous pressure of mouse eye and effect of body position. Curr Eye Res 2003; 27:355-362. Aqueous humor dynamics can be measured in the mouse eye. Aqueous production and calculated aqueous turnover rate is similar to human eyes.
24. Savinova OV, Sugiyama F, Martin JE, et al. Intraocular pressure in genetically distinct mice: an update and strain survey. BMC Genet 2001; 2:12.
25. Lindsey JD, Weinreb RN. Identification of the mouse uveoscleral outflow pathway using fluorescent dextran. Invest Ophthalmol Vis Sci 2002; 43:2201-2205.
26. Bernd AS, Aihara M, Lindsey JD, et al. Influence of molecular weight on intra-cameral dextran movement to the posterior segment of the mouse eye. Invest Ophthalmol Vis Sci 2004; 45:480-484.
27. Crowston JG, Aihara M, Lindsey JD, et al. Effect of latanoprost on outflow facility in the mouse. Invest Ophthalmol Vis Sci 2004; 45:2240-2245.
28. Crowston JG, Lindsey JD, Aihara M, et al. Effect of latanoprost on intraocular pressure in mice lacking the prostaglandin FP receptor. Invest Ophthalmol Vis Sci 2004; 45:3555-3559.
29. Brubaker RF. Targeting outflow facility in glaucoma management. Surv Ophthalmol 2003; 48(Suppl 1):S17-S20. Increased outflow facility may stabilize as well as lower IOP and therefore may provide an attractive target for glaucoma treatment.
30. Miller D. The relationship between diurnal tension variation and the water-drinking test. Am J Ophthalmol 1964; 58:243-246.
31. Medeiros FA, Pinheiro A, Moura FC, et al. Intraocular pressure fluctuations in medical versus surgically treated glaucomatous patients. J Ocul Pharmacol Ther 2002; 18:489-498.
32. Susanna R Jr, Sheu WP. Comparison of latanoprost with fixed-combination dorzolamide and timolol in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label, parallel-group, multicenter study in Latin America. Clin Ther 2004; 26:755-768. A prospective randomized comparison of latanoprost with a fixed dorzolamide/timolol combination. Mean IOP was similar in the two treatment groups, but latanoprost-treated eyes had a lower peak IOP during the water drinking test.
33. Kaufman PL. Epinephrine, norepinephrine, and isoproterenol dose-outflow facility response relationships in cynomolgus monkey eyes with and without ciliary muscle retrodisplacement. Acta Ophthalmol (Copenh) 1986; 64:356-363.
34. Kaufman PL, Barany EH. Loss of acute pilocarpine effect on outflow facility following surgical disinsertion and retrodisplacement of the ciliary muscle from the scleral spur in the cynomolgus monkey. Invest Ophthalmol 1976; 15:793-807.
35. Toris CB, Gleason ML, Camras CB, et al. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol 1995; 113:1514-1517.
36. Toris CB, Camras CB, Yablonski ME. Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients. Am J Ophthalmol 1999; 128:8-14.
37. Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology 1993; 100:1297-1304.
38. Ziai N, Dolan JW, Kacere RD, et al. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol 1993; 111:1351-1358.
39. Toris CB, Zhan GL, Zhao J, et al. Potential mechanism for the additivity of pilocarpine and latanoprost. Am J Ophthalmol 2001; 131:722-728.
40. Serle JB, Podos SM, Kitazawa Y, et al. A comparative study of latanoprost (Xalatan) and isopropyl unoprostone (Rescula) in normal and glaucomatous monkey eyes. Jpn J Ophthalmol 1998; 42:95-100.
41. Saito M, Takano R, Shirato S. Effects of latanoprost and unoprostone when used alone or in combination for open-angle glaucoma. Am J Ophthalmol 2001; 132:485-489.
42. Takagi Y, Nakajima T, Shimazaki A, et al. Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. Exp Eye Res 2004; 78:767-776.
43. 2 increased pressure insensitive outflow but had no effect on outflow facility in cynomolgus monkeys.
44. Brubaker RF, Schoff EO, Nau CB, et al. Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. Am J Ophthalmol 2001; 131:19-24.
45. Toris CB, Zhan GL, McLaughlin MA. Effects of brinzolamide on aqueous humor dynamics in monkeys and rabbits. J Ocul Pharmacol Ther 2003; 19:397-404.
46. Walters TR, DuBiner HB, Carpenter SP, et al. 24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial. Surv Ophthalmol 2004; 49(Suppl 1):S26-S35.
47. Liu JH, Kripke DF, Weinreb RN. Comparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure. Am J Ophthalmol 2004; 138:389-395. Latanoprost and timolol significantly lowered diurnal IOP in ocular hypertensive and early glaucomatous eye. Only latanoprost reduced nocturnal supine IOP.
48. Kiland JA, Gabelt BT, Kaufman PL. Studies on the mechanism of action of timolol and on the effects of suppression and redirection of aqueous flow on outflow facility. Exp Eye Res 2004; 78:639-651. Decreasing aqueous humor formation in combination with therapy that increases uveoscleral outflow and diverts aqueous humor from the trabecular meshwork can reduce outflow facility.
49. Sagara T, Gaton DD, Lindsey JD, et al. Topical prostaglandin F2alpha treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway. Arch Ophthalmol 1999; 117:794-801.
50. Weinreb RN, Kashiwagi K, Kashiwagi F, et al. Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest Ophthalmol Vis Sci 1997; 38:2772-2780.
51. Lindsey JD, Kashiwagi K, Boyle D, et al. Prostaglandins increase proMMP-1 and proMMP-3 secretion by human ciliary smooth muscle cells. Curr Eye Res 1996; 15:869-875.
52. Ocklind A. Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections. Exp Eye Res 1998; 67:179-191.
53. Gaton DD, Sagara T, Lindsey JD, et al. Increased matrix metalloproteinases 1, 2, and 3 in the monkey uveoscleral outflow pathway after topical prostaglandin F(2 alpha)-isopropyl ester treatment. Arch Ophthalmol 2001; 119:1165-1170.
54. Richter M, Krauss AH, Woodward DF, et al. Morphological changes in the anterior eye segment after long-term treatment with different receptor selective prostaglandin agonists and a prostamide. Invest Ophthalmol Vis Sci 2003; 44:4419-4426.
55. Lutjen-Drecoll E, Kaufman PL. Biomechanics of echothiophate-induced anatomic changes in monkey aqueous outflow system. Graefes Arch Clin Exp Ophthalmol 1986; 224:564-575.
56. Gottanka J, Chan D, Eichhorn M, et al. Effects of TGF-beta-2 in perfused human eyes. Invest Ophthalmol Vis Sci 2004; 45:153-158.
57. Santas AJ, Bahler C, Peterson JA, et al. Effect of heparin II domain of fibronectin on aqueous outflow in cultured anterior segments of human eyes. Invest Ophthalmol Vis Sci 2003; 44:4796-4804.
58. Tian B, Kaufman PL, Volberg T, et al. H-7 disrupts the actin cytoskeleton and increases outflow facility. Arch Ophthalmol 1998; 116:633-643.
59. Tian B, Wang RF, Podos SM, et al. Effects of topical H-7 on outflow facility, intraocular pressure, and corneal thickness in monkeys. Arch Ophthalmol 2004; 122:1171-1177.
60. Gabelt BT, Hennes EA, Seeman JL, et al. H-7 effect on outflow facility after trabecular obstruction following long-term echothiophate treatment in monkeys. Invest Ophthalmol Vis Sci 2004; 45:2732-2736.
61. Pang IH, Fleenor DL, Hellberg PE, et al. Aqueous outflow-enhancing effect of tert-butylhydroquinone: involvement of AP-1 activation and MMP-3 expression. Invest Ophthalmol Vis Sci 2003; 44:3502-3510.